MicroRNAs: the novel targets for Ebola drugs by unknown
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2014. This article is published with open access at link.springer.com life.scichina.com   link.springer.com 
                  
*Corresponding author (email: yanjh@im.ac.cn) 
SPECIAL TOPIC: Potential remedies against Ebola virus diseases October 2014  Vol.57  No.10: 985–986 
• COMMENTARY • doi: 10.1007/s11427-014-4750-y  
MicroRNAs: the novel targets for Ebola drugs 
YAN JingHua1* & GAO George Fu1,2,3,4 
1CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, 
China; 
2Research Network of Immunity and Health, Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China; 
3National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; 
4Office of Director-General, Chinese Center for Disease Control and Prevention, Beijing 102206, China 
Received September 2, 2014; accepted September 5, 2014; published online September 17, 2014 
 




The re-emergence of Ebola viral disease (EVD) in West 
Africa has caused an international alarm, even panic. As of 
August 27th, 2014, the Ebola virus (EBOV) has infected 
3069 people with 1552 death cases starting from December 
2013 (http://www.who.int/csr/don/2014_08_28_ebola/en/). 
Recently, an outbreak of Ebola hemorrhagic fever in the 
north of Congo (Democratic Republic) has been confirmed 
besides Guinea, Liberia, Sierra Leone and Nigeria. So far 
the epidemic has not been effectively controlled. 
Vascular endothelial cell permeability mainly contributes 
to the hemorrhagic fever during EBOV infection and the 
consequent high mortality. However, the complete mecha-
nism leading to changes in vascular endothelial cell perme-
ability have not been elucidated. Several factors, including 
the release of inflammatory mediators, virus directed at-
tacking of endothelium, the release of endosomal cathepsins 
and the expression of virus-envelope glycoprotein GP, are 
proposed to be responsible for virus-induced cell injury and 
the vascular permeability [1]. GP is considered as a viral 
determinant of EBOV pathogenicity and likely contributes 
to hemorrhage during infection, as several groups reported 
that overexpression of GP can induce cell detachment and 
rounding in vitro and ex vivo [2]. Similar results were also 
confirmed by Prof. Jiang and her colleagues [3]. 
In the article published in this issue, Sheng et al. [3] at-
tempted to explore the molecule mechanism by which GP 
induces cell damage from a new angle. They evaluated the 
microRNA levels, using the RNA-Seq method, in human 
umbilical endothelial cells (HUVECs) that overexpress 
EBOV GP. At least 18 microRNAs were differentially ex-
pressed with high significance in the GP-expressing cells 
compared to in the GP-negative cells. To investigate the 
role of those microRNAs in EBOV pathogenesis, the au-
thors knocked down the candidate microRNAs in the 
GP-expressing cells with microRNA inhibitors. Three mi-
croRNA inhibitors, hsa-miR-1246, hsa-miR-320a and 
hsa-miR-196b-5p, were found to effectively ameliorate the 
GP-induced cell detachment and rounding. To the best of 
our knowledge, this is the first time that solid evidence is 
presented to show that microRNAs are involved in the 
GP-mediated cell damage.  
MicroRNAs are oligo-nucleotides of approximate 21–23 
bp in size. These single-stranded noncoding RNA molecules 
have been identified as one of the most important 
gene-expression regulators in various physiological pro-
cesses. In general, they silence the expression of their target 
genes via degradation of the mRNA or by translational re-
pression. In the paper of Sheng et al. [3], the target genes of 
hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p were 
predicted using the miRDB database. They further analyzed 
the expression levels of those genes in the GP-expressing 
cells by Western blotting and found that seven out of 21 
predicted genes were down-regulated comparing with the 
negative controls. One of the main attractions of their re-
sults is that the microRNA inhibitor treatment of HUVECs 
could result in an increased expression of TFPI (tissue fac-
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tor pathway inhibitor), DAG1 (dystrophin-associated gly-
coprotein 1) and CFLAR (CASP8 and FADD-like apoptosis 
regulator). All the three proteins have been previously 
shown to be associated with cell adhesion and cell survival. 
TFPI is the primary factor inhibiting the initiation of blood 
coagulation and can modulate the severity of a wide variety 
of bleeding and clotting disorders. DAG1 is involved in a 
number of processes including laminin and basement mem-
brane assembly, cell survival, cell migration, and epithelial 
polarization. CFLAR is a key anti-apoptotic regulator that 
inhibits cell death mediated by the death receptors Fas, DR4, 
DR5, and TNF-R1. Therefore, it is reasonable to infer that 
hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p were 
involved in Ebola GP-mediated cellular damage through 
down-regulating the target proteins of TFPI, DAG1 and 
CFLAR. Their further studies showed that the GP-mediated 
cytotoxicity could be rescued when microRNA inhibitors or 
the target-gene (TFPI, DAG1and CFLAR) expression plas-
mids were transfected into HUVECs or 293T cells that 
overexpress EBOV GP. Jiang’s results developed a new 
scientific niche for studies on the GP-mediated cytotoxicity 
and the EBOV pathogenic signaling pathways, and provided 
a new target for EBOV drug development. 
So far, Ebola inhibitors/drugs and vaccines still stuck in 
laboratories [4]. There are no approved drugs for treatment 
of Ebola patients or vaccines to protect the people of high 
exposure risks from Ebola infection. Under the pressure of 
the urgent circumstances in West Africa, World Health Or-
ganization (WHO) committee suggested, upon the patients’ 
informed consent, to use unproven drugs (e.g., Zmapp) and 
vaccines to control the pandemic. Studies from Jiang’s 
group indicated that inhibitors of hsa-miR-1246, hsa-miR- 
320a and hsa-miR-196b-5p can alleviate GP-induced cell 
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